Your browser doesn't support javascript.
loading
Androgen Receptor Signaling in Salivary Gland Cancer.
Dalin, Martin G; Watson, Philip A; Ho, Alan L; Morris, Luc G T.
Afiliação
  • Dalin MG; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. martin.dalin@gu.se.
  • Watson PA; Department of Pediatrics, Institution for Clinical Sciences, University of Gothenburg, Gothenburg SE-416 86, Sweden. martin.dalin@gu.se.
  • Ho AL; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. watsonp@mskcc.org.
  • Morris LG; Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. hoa@mskcc.org.
Cancers (Basel) ; 9(2)2017 Feb 08.
Article em En | MEDLINE | ID: mdl-28208703
Salivary gland cancers comprise a small subset of human malignancies, and are classified into multiple subtypes that exhibit diverse histology, molecular biology and clinical presentation. Local disease is potentially curable with surgery, which may be combined with adjuvant radiotherapy. However, metastatic or unresectable tumors rarely respond to chemotherapy and carry a poorer prognosis. Recent molecular studies have shown evidence of androgen receptor signaling in several types of salivary gland cancer, mainly salivary duct carcinoma. Successful treatment with anti-androgen therapy in other androgen receptor-positive malignancies such as prostate and breast cancer has inspired researchers to investigate this treatment in salivary gland cancer as well. In this review, we describe the prevalence, biology, and therapeutic implications of androgen receptor signaling in salivary gland cancer.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2017 Tipo de documento: Article